Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/154068
Title: Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC β-lactamase-producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens : a pilot multicenter randomized controlled trial (MERINO-2)
Authors: Stewart, Adam G.
Paterson, David L.
Young, Barnaby
Lye, David C.
Davis, Joshua S.
Schneider, Kellie
Yilmaz, Mesut
Dinleyici, Rumeysa
Runnegar, Naomi
Henderson, Andrew
Archuleta, Sophia
Kalimuddin, Shirin
Forde, Brian M.
Chatfield, Mark D.
Bauer, Michelle J.
Lipman, Jeffrey
Harris-Brown, Tiffany
Harris, Patrick N. A.
Keywords: Science::Medicine
Issue Date: 2021
Source: Stewart, A. G., Paterson, D. L., Young, B., Lye, D. C., Davis, J. S., Schneider, K., Yilmaz, M., Dinleyici, R., Runnegar, N., Henderson, A., Archuleta, S., Kalimuddin, S., Forde, B. M., Chatfield, M. D., Bauer, M. J., Lipman, J., Harris-Brown, T. & Harris, P. N. A. (2021). Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC β-lactamase-producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens : a pilot multicenter randomized controlled trial (MERINO-2). Open Forum Infectious Diseases, 8(8), ofab387-. https://dx.doi.org/10.1093/ofid/ofab387
Journal: Open Forum Infectious Diseases
Abstract: Background: Carbapenems are recommended treatment for serious infections caused by AmpC-producing gram-negative bacteria but can select for carbapenem resistance. Piperacillin-tazobactam may be a suitable alternative. Methods We enrolled adult patients with bloodstream infection due to chromosomal AmpC producers in a multicenter randomized controlled trial. Patients were assigned 1:1 to receive piperacillin-tazobactam 4.5 g every 6 hours or meropenem 1 g every 8 hours. The primary efficacy outcome was a composite of death, clinical failure, microbiological failure, and microbiological relapse at 30 days. Results Seventy-two patients underwent randomization and were included in the primary analysis population. Eleven of 38 patients (29%) randomized to piperacillin-tazobactam met the primary outcome compared with 7 of 34 patients (21%) in the meropenem group (risk difference, 8% [95% confidence interval {CI}, –12% to 28%]). Effects were consistent in an analysis of the per-protocol population. Within the subcomponents of the primary outcome, 5 of 38 (13%) experienced microbiological failure in the piperacillin-tazobactam group compared to 0 of 34 patients (0%) in the meropenem group (risk difference, 13% [95% CI, 2% to 24%]). In contrast, 0% vs 9% of microbiological relapses were seen in the piperacillin-tazobactam and meropenem arms, respectively. Susceptibility to piperacillin-tazobactam and meropenem using broth microdilution was found in 96.5% and 100% of isolates, respectively. The most common AmpC β-lactamase genes identified were blaCMY-2, blaDHA-17, blaCMH-3, and blaACT-17. No ESBL, OXA, or other carbapenemase genes were identified. Conclusions Among patients with bloodstream infection due to AmpC producers, piperacillin-tazobactam may lead to more microbiological failures, although fewer microbiological relapses were seen.
URI: https://hdl.handle.net/10356/154068
ISSN: 2328-8957
DOI: 10.1093/ofid/ofab387
Rights: © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com https://doi.org/10.1093/ofid/ofab387
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
ofab387.pdf727.45 kBAdobe PDFView/Open

Page view(s)

16
Updated on May 15, 2022

Download(s)

15
Updated on May 15, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.